In people with type 2 diabetes receiving lixisenatide alone, derived time-in-range improved by 11.7% from baseline to treatment end.
In plain wordsIn people with diabetes receiving lixisenatide alone, time in glucose range increased from baseline.
- Peptide
- Lixisenatide
- Outcome
- IncreaseDerived time-in-range change with lixisenatide alone
- Study
n = 234
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- dTIR improvement
- 11.7%
- Lixi
Source sentences
Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%).
3 context sentences(design, population, supporting numbers)
To evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR).
Participant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (> 180 mg/dL) and derived time-below-range (dTBR; < 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles.
This pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257).